Rich Pharma India Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 08-07-2024
- Paid Up Capital ₹ 5.00 M
as on 08-07-2024
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2016
- Open Charges ₹ 5.04 Cr
as on 08-07-2024
- Satisfied Charges ₹ 3.95 M
as on 08-07-2024
- Revenue -18.15%
(FY 2016)
- Profit -43.02%
(FY 2016)
- Ebitda -47.79%
(FY 2016)
- Net Worth 4.44%
(FY 2016)
- Total Assets -9.76%
(FY 2016)
About Rich Pharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2016. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹5.04 Cr. The company has closed loans amounting to ₹3.95 M, as per Ministry of Corporate Affairs (MCA) records.
Atul Girme, Jayashree Gawade, and Rohit Girme serve as directors at the Company.
- CIN/LLPIN
U24239PN2008PTC131753
- Company No.
131753
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Apr 2008
- Date of AGM
30 Sep 2016
- Date of Balance Sheet
31 Mar 2016
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rich Pharma India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Atul Girme  | Director | 20-May-2016 | Current |
| Jayashree Gawade | Director | 01-Sep-2014 | Current |
| Rohit Girme | Director | 01-Oct-2013 | Current |
Financial Performance of Rich Pharma India.
Rich Pharma India Private Limited., for the financial year ended 2016, experienced significant reduction in revenue, with a 18.15% decrease. The company also saw a substantial fall in profitability, with a 43.02% decrease in profit. The company's net worth moved up by a moderate rise of 4.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rich Pharma India?
In 2016, Rich Pharma India had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Karad Urban Co-Operative Bank Ltd. Creation Date: 13 Aug 2013 | ₹0.40 M | Open |
The Karad Urban Co-Operative Bank Ltd. Creation Date: 13 Aug 2013 | ₹5.00 Cr | Open |
Syndicate Bank Creation Date: 16 Nov 2009 | ₹0.95 M | Satisfied |
How Many Employees Work at Rich Pharma India?
Unlock and access historical data on people associated with Rich Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rich Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rich Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
